FATE News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

FA

Mkt Cap

$213.8M

Volume

1.27M

Next Earnings

November 12th

Loading chart

FA

FATEFate Therapeutics, Inc.

FATE

Pay with—

Available Balance0.00

FA

Mkt Cap

$230.7M

Volume

1.27M

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell TherapiesFate Therapeutics announced the appointment of Jamie Harrell as Senior Vice President of Market Development & Commercial Operations to lead commercialization of its CAR T-cell therapies. Harrell brings over 25 years of commercial leadership experience, including expertise in launching first-in-class autoimmune therapies and establishing lupus treatments. He will oversee commercial strategy for FT819 (in Phase 2 RECLAIM-LN trial for lupus nephritis) and FT839 (Phase 1/2 trial for autoimmune indications), with focus on enabling outpatient administration in community settings.GlobeNewswire Inc. · Oct 12, 2026

Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 ConferencesFate Therapeutics announced that management will participate in two major investor conferences in Q4 2026: the Jefferies Global Healthcare Conference in London (November 16-19) and the Piper Sandler 38th Annual Healthcare Conference in New York (December 1-3). Live webcasts will be available on the company's investor website.GlobeNewswire Inc. · Oct 1, 2026

Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026Fate Therapeutics announced that four abstracts from its off-the-shelf CAR T-cell programs have been selected for presentation at ACR Convergence 2026. The presentations will showcase clinical data for FT819, including administration without conditioning chemotherapy and outpatient administration capabilities, as well as updates on the Phase 1/2 COMPLETE Trial for FT839, a dual-CAR T-cell candidate targeting CD19 and CD38 for autoimmune diseases.GlobeNewswire Inc. · Sep 16, 2026

Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026–2036), as Innovative Therapies Gain Momentum | DelveInsightThe lupus nephritis market is projected to grow at a 7% CAGR through 2036, driven by increasing disease awareness, improved diagnosis, and expanding adoption of targeted therapies. The market was valued at USD 2.1 billion in 2025 across seven major markets. Three therapies have received FDA approval (belimumab, voclosporin, and obinutuzumab), while a robust pipeline of innovative treatments including CAR-T therapies, complement inhibitors, and monoclonal antibodies is expected to transform disease management.GlobeNewswire Inc. · Sep 14, 2026

Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsightThe lupus nephritis drug development pipeline is rapidly expanding with 30+ pharmaceutical companies developing 35+ pipeline therapies across various clinical stages. Key players including Novartis, Simcere Pharmaceutical, Kyverna Therapeutics, Century Therapeutics, and Adicet Bio are advancing promising treatments with novel mechanisms of action such as BAFF-R inhibitors, CAR-NK cell therapies, and anti-CD19/CD20 approaches. Recent regulatory milestones include FDA RMAT designations for cell therapies and positive Phase III trial results, indicating accelerating progress in addressing this serious autoimmune kidney disease.GlobeNewswire Inc. · Jun 10, 2026

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative MarketsCell-based therapies are emerging as a transformative approach in healthcare, with the global cell therapy market expected to grow from $4.7 billion in 2023 to over $20 billion by 2030. Several biotech companies announced significant milestones: Avaí Bio and Austrianova completed a Master Cell Bank for α-Klotho anti-aging therapy; Geron presented real-world evidence for RYTELO in myelodysplastic syndromes; BioAge Labs reported Phase 1 results for BGE-102 showing strong inflammatory biomarker reductions; Lineage Cell Therapeutics presented 3-year data for OpRegen cell therapy in geographic atrophy; and Fate Therapeutics advanced FT819 CAR T-cell therapy with FDA recognition.Benzinga · May 20, 2026

Scalable Biotech Manufacturing Unlocks a $14B MarketThe global cell therapy manufacturing market is projected to reach $14 billion by 2035, driven by over 1,000 active clinical candidates. FDA regulatory flexibility is accelerating timelines for cell and gene therapy approvals. Several biotech companies are advancing scalable manufacturing capabilities and clinical programs: Avaí Bio is producing Master Cell Banks for α-Klotho therapy; ImmunityBio validated scalable NK cell manufacturing; Fate Therapeutics achieved outpatient CAR T-cell therapy for autoimmune diseases; Fractyl Health completed pivotal trial randomization for GLP-1 weight maintenance; and Moleculin Biotech enrolled its 45th subject in a Phase 2B/3 AML trial.Benzinga · Mar 27, 2026

Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind ThemThe global cell therapy market is projected to surpass $8.2 billion in 2026, with CAR T-cell therapy expanding at 18% annually. Several companies are advancing manufacturing milestones and clinical breakthroughs: Avaí Bio initiated Master Cell Bank production for α-Klotho anti-aging therapy; FibroBiologics secured a patent for fibroblast cell therapy for osteoporosis; Fate Therapeutics achieved same-day hospital discharge for off-the-shelf CAR T-cell patients; Mesoblast presented favorable survival data for Ryoncil® in graft-versus-host disease; and Longeveron published Phase 2b results showing stem cell therapy improved physical condition in age-related frailty patients.Benzinga · Mar 3, 2026

IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightThe iPSC-derived NK cells clinical trial pipeline is experiencing significant momentum with 12+ companies developing 15+ pipeline therapies. Key players including Century Therapeutics, Fate Therapeutics, Cartherics, and others are advancing promising candidates like CNTY-101, FT522, and CTH-401 across various clinical stages. Recent developments include Century's CNTY-101 continuation in Phase I/II trials and Fate's positive initial data from FT522 in relapsed/refractory B-cell lymphoma, positioning iPSC-derived NK cells as a cornerstone of next-generation cancer immunotherapy.GlobeNewswire Inc. · Feb 16, 2026

Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease MarketsThe biotech sector is experiencing significant growth driven by FDA regulatory shifts favoring advanced cell and gene therapies. Companies like Avant Technologies, MannKind, Vertex Pharmaceuticals, Fate Therapeutics, and Ardelyx are positioned to benefit from a projected $88.85 billion next-gen treatment market by 2030 and $9.06 trillion biotech sector by 2035. Key catalysts include FDA approvals, clinical trial progress, and record revenue achievements across multiple therapeutic areas including diabetes, kidney disease, and rare genetic disorders.GlobeNewswire Inc. · Jan 23, 2026

to start trading

FA

FATEFate Therapeutics, Inc.

FATE

Pay with—

Available Balance0.00

Your PositionYou don't own any FATE yet.

Related Tickers

Earnings